Investor relations:

Mirabilis Therapeutics is currently a privately-held company. For more information on investment possibilities please contact Jan Wit through

Business Development:

Mirabilis Therapeutics intends to form strategic alliances with companies that have added-value technologies in the microRNA space or otherwise and that will excel Mirabilis Therapeutics’ first product to market. Mirabilis Therapeutics' particular interest is to find and establish partnerships in the cardiovascular and metabolic disease areas.